Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display
Metrics: PDF 1729 views | HTML 2678 views | ?
Anders Tveita1, Marte Fauskanger1, Bjarne Bogen1,2, Ole Audun Werner Haabeth1
1Centre for Immune Regulation, Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
2KG Jebsen Centre for Research on Influenza Vaccines, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
Ole Audun Werner Haabeth, email: [email protected]
Bjarne Bogen, email: [email protected]
Keywords: CD4+ T cells, MHC class II, tumor immunology, antigen presentation, anti-tumor immunity
Received: May 06, 2016 Accepted: September 02, 2016 Published: September 10, 2016
CD4+ T cells have been shown to reject tumor cells with no detectable expression of major histocompatibility complex class II (MHC II). However, under certain circumstances, induction of ectopic MHC II expression on tumor cells has been reported.
To confirm that CD4+ T cell-mediated anti-tumor immunity can be successful in the complete absence of antigen display on the tumor cells themselves, we eliminated MHC II on tumor cells using CRISPR/Cas9. Our results demonstrate that ablation of the relevant MHC II (I-Ed) in multiple myeloma cells (MOPC315) does not hinder rejection by tumor-specific CD4+ T cells. These findings provide conclusive evidence that CD4+ T cells specific for tumor antigens can eliminate malignant cells in the absence of endogenous MHC class II expression on the tumor cells. This occurs through antigen uptake and indirect presentation on tumor-infiltrating macrophages.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.